Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris : case series and review of the literature
| Autor: | Andreas Pinter, Ahmad Jalili, Flavia Angeletti, Henrik Thormann |
|---|---|
| Přispěvatelé: | Weinberg, Jeffrey, Norman, Amy |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class aerosol Betamethasone dipropionate calcipotriol Dermatology law.invention 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Psoriasis medicine In patient Case Series ddc:610 Calcipotriol Aerosol Foam betamethasone dipropionate business.industry psoriasis medicine.disease Tolerability chemistry Clinical Cosmetic and Investigational Dermatology 030220 oncology & carcinogenesis Corticosteroid business medicine.drug |
| Zdroj: | Clinical, Cosmetic and Investigational Dermatology |
| Popis: | Andreas Pinter,1 Henrik Thormann,2 Flavia Angeletti,1 Ahmad Jalili3 1Department of Dermatology, Venereology, and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany; 2Dermatology Clinic, Vejle, Denmark; 3Department of Dermatology, Bürgenstock Medical Center, Obbürgen, Switzerland Abstract: An aerosol foam formulation of a once-daily, fixed-dose combination of a synthetic vitamin D3 analog/synthetic corticosteroid (calcipotriol [Cal] 50µg/g and betamethasone dipropionate [BD] 0.5mg/g) has recently been introduced for the topical treatment of plaque psoriasis in adults. Data from several sources – randomized controlled trials, case reports (as highlighted in this review), and real-world evidence (RWE) – underscore the considerable and rapid clinical response, effectiveness, and favorable safety and tolerability of Cal/BD aerosol foam in mild-to-moderate psoriatic patients previously treated with class 3 or 4 topical corticosteroids, in patients unsatisfied with ongoing phototherapy in combination with topical therapy and in patients with moderate-to-severe psoriasis. In addition, our case series, considered together with other RWE, highlights that Cal/BD aerosol foam is more effective and with greater levels of patient preference and acceptability than comparator preparations. Thus, Cal/BD aerosol foam offers several treatment advantages, including relief of itch, and is an appropriate first-line topical therapy for consideration in patients with psoriasis of any severity. Keywords: aerosol, betamethasone dipropionate, calcipotriol, psoriasis |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|